Guillain-Barre syndrome

ANNA JULIA LACERDA RAPOSO; EDUARDO GALVÃO FREIRE; CÉLIA RAIANY FERREIRA DE FARIAS; E PINHEIRO RENATO SERQUIZ; FRANCISCO IROCHIMA PINHEIRO; FAUSTO PIERDONÁ GUZEN; AMÁLIA CINHTIA MENESES RÊGO; IRAMI ARAÚJO-FILHO

doi:10.30574/gscbps.2019.9.1.0198

Authors

ANNA JULIA LACERDA RAPOSO Undergraduate Student of Medicine at UnP - Potiguar University - Laureate International Universities – Natal/Brazil.
EDUARDO GALVÃO FREIRE Undergraduate Student of Medicine at UnP - Potiguar University - Laureate International Universities – Natal/Brazil.
CÉLIA RAIANY FERREIRA DE FARIAS Undergraduate Student of Medicine at UnP - Potiguar University - Laureate International Universities – Natal/Brazil.
E PINHEIRO RENATO SERQUIZ Neurologist and Professor at Potiguar University / UnP - Laureate International Universities – Natal/Brazil.
FRANCISCO IROCHIMA PINHEIRO Postgraduate Program in Biotechnology at Potiguar University/ UnP - Laureate International Universities – Natal/Brazil. Ph.D. in Health Science.
FAUSTO PIERDONÁ GUZEN Postgraduate Program in Biotechnology at Potiguar University/ UnP - Laureate International Universities – Natal/Brazil. Ph.D. in Health Science.
AMÁLIA CINHTIA MENESES RÊGO Postgraduate Program in Biotechnology at Potiguar University/ UnP - Laureate International Universities – Natal/Brazil. Ph.D. in Health Science.
IRAMI ARAÚJO-FILHO Postgraduate Program in Biotechnology at Potiguar University/ UnP - Laureate International Universities – Natal/Brazil. Ph.D. in Health Science.

DOI:

https://doi.org/10.30574/gscbps.2019.9.1.0198

Keywords:

Guillain-Barre syndrome, Acute infectious polyneuritis, Acute autoimmune neuropathy, Acute inflammatory demyelinating polyneuropathy, Inflammatory polyneuropathy acute

Abstract

Guillain-Barre syndrome is the most common and most severe acute flaccid paralysis, usually preceded by an infection or immune stimulation. A literature review of the last five years in Pubmed, Scopus, Embase, and Web of Science databases was done. Data were collected from epidemiological studies using the keywords. Guillain-Barrè syndrome (GBS) is an acute, severe, and fulminant polyradiculoneuropathy. It has ascending muscle weakness, rapid evolution, the involvement of respiratory muscles with an evolution period of up to four weeks. It has the Classic and Variant forms of clinical presentation. Guillain-Barrè Syndrome is a rapidly progressive disease. The diagnosis is clinical but requires exams such as electroneuromyography and cerebrospinal fluid analysis, so that treatment can be started as soon as possible to improve prognosis and increase survival of affected patients.

Metrics

Metrics Loading ...

References

Wakerley BR and Yuki N. (2014). Pharyngeal-cervical-brachial variant of Guillain–Barré syndrome. J Neurol Neurosurg Psychiatry, 85(3), 339-44.

Beattie J, Parajuli S, Sanger M, Lee G, Pleninger P, Crowley G, Kwon S, Murthy V, Manko JA, Caplan A, Dufort E, Pastula DM and Nolan A. (2018). Zika Virus-Associated Guillain-Barré Syndrome in a Returning US Traveler. Infect Dis Clin Pract, 26(6), e80-e84.

L Peña, Moreno CB and Gutierrez-Alvarez AM. (2015). Pain management in Guillain-Barre syndrome: A systematic review. Neurologia, 30(7), 433-438.

Azevedo MB, Coutinho MSC, Silva MAD, Arduini DB, Lima JDV, Monteiro R, Mendes BNB, Lemos MCF, Noronha CP and Saraceni V. (2018). Neurologic manifestations in emerging arboviral diseases in Rio de Janeiro City, Brazil, 2015-2016. Rev Soc Bras Med Trop, 51(3), 347-351.

Eldar AH and Chapman J. (2014). Guillain Barré syndrome and other immune mediated neuropathies: Diagnosis and classification. Autoimmunity Reviews, 13(4-5), 525-30.

Wijdicks EF and Klein CJ. (2017). Guillain-Barré Syndrome. Mayo Clinic Proceedings, 92(3), 467-479.

Edmundson C and Bird SJ. (2019). Acute Manifestations of Neuromuscular Disease. Thieme Medical Publishers, 39(1), 115-124.

Motamed-Gorji N, Matin N, Tabatabaie O, Pavone P, Romano C, Falsaperla R and Vitaliti G. (2017). Biological Drugs in Guillain-Barré Syndrome: An Update. Curr Neuropharmacol, 15(7), 938-950.

Goodfellow JA and Willison HJ. (2016). Guillain–Barré syndrome: a century of progress. Nature Reviews Neurology, 12(12), 723-731.

Willison HJ, Jacobs BC and Doorn PAV. (2016). Guillian-Barré syndrome. Lancet, 13, 388(10045), 717-727.

Esposito S and Longo MR. (2017). Guillain–Barré syndrome. Autoimmun Rev, 16(1), 96-101.

Kaushik R, Kharbanda PS, Bhalla A, Rajan R and Prabhakar S. (2014). Acute Flaccid paralysis in adults: Our experience. J Emerg Trauma Shock, 7(3), 149-54.

Créange A. (2016). Guillain-Barré syndrome: 100 years on. Revue Neurologique, 172(12), 770–774.

Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, Harbo T, Hartung HP, Hughes RAC, Kusunoki S, van Doorn PA and Willison HJ; IGOS Consortium. (2017). International Guillain-Barré Syndrome Outcome Study: protocol of aprospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. J Peripher Nerv Syst, 22(2), 68-76.

Hughes RAC, Cornblath DR and Willison HJ. (2016) Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl. Brain, 139(11), 3041–3047.

Jasti AK, Selmi C, Sarmiento-Monroy JC, Vega DA, Anaya JM and Gershwin ME. (2016). Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment. Expert Rev Clin Immunol, 12(11), 1175-1189.

Fadia M, Shroff S and Simpson E. (2019). Immune-Mediated Neuropathies. Curr Treat Options Neurol, 21(6), 28.

Bowley MP and Chad DA. (2019). Clinical neurophysiology of demyelinating polyneuropathy.Handbook of Clinical Neurology, 161(3), 241–268.

Chakraborty T, Kramer CL, Wijdicks EFM and Rabinstein AA. (2019). Dysautonomia in Guillain–Barré Syndrome: Prevalence, Clinical Spectrum, and Outcomes. Neurocrit Care, 11.

Doets AY, Jacobs BC and van Doorn PA. (2018). Advances in management of Guillain-Barré syndrome. Current Opinion in Neurology, 31(5), 541–550.

Oaklander AL and Nolano M. (2019). Scientific Advances in and Clinical Approaches to Small-Fiber Polyneuropathy: A Review. JAMA Neurol.